Myelofibrosis in 2019: moving beyond JAK2 inhibition

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia. The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as...

Descripción completa

Detalles Bibliográficos
Autores principales: Schieber, Michael, Crispino, John D., Stein, Brady
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739355/
https://www.ncbi.nlm.nih.gov/pubmed/31511492
http://dx.doi.org/10.1038/s41408-019-0236-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739355/
https://www.ncbi.nlm.nih.gov/pubmed/31511492
http://dx.doi.org/10.1038/s41408-019-0236-2

Ejemplares similares